Announced details
Endoscopic administration of oncolytic adenovirus without limitation to cancer type, expansion of the indications for OBP-301, and potential use in OBP-702
The company plans to expand the area covered by the patent to major European countries, including the United Kingdom, France and Germany.
The company has filed a European patent application.
The European authority responsible for patent examination and grant procedures. Other details: Not disclosed.
European Patent Office
Japan: Patent No. 7674738; Japanese Patent Application No. 2025-068907. Europe: notification of intention to grant a patent. The patent is expected to remain in force until May 2040 following registration.
The impact on the Company's financial results for the fiscal year ending December 2026 is expected to be minor.
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Oncolytic virus OBP-301, OBP-702 |
| Counterparty | European Patent Office |
| Counterparty overview | The European authority responsible for patent examination and grant procedures. Other details: Not disclosed. |
| Relationship with the Company | The company has filed a European patent application. |
| Applicable area | Endoscopic administration of oncolytic adenovirus without limitation to cancer type, expansion of the indications for OBP-301, and potential use in OBP-702 |
| Awarding / certifying body | European Patent Office |
| Registration number and expiry date | Japan: Patent No. 7674738; Japanese Patent Application No. 2025-068907. Europe: notification of intention to grant a patent. The patent is expected to remain in force until May 2040 following registration. |
| Quantitative Effects | The company plans to expand the area covered by the patent to major European countries, including the United Kingdom, France and Germany. |
| Impact on Business Performance | The impact on the Company's financial results for the fiscal year ending December 2026 is expected to be minor. |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The European Patent Office indicated its intention to grant a European patent based on the current application.